XYRA Announces Issuance of US Patent to Reduce the Risk of Heart Failure or Strokes by Reducing the Number and Duration of Atrial Fibrillations

XYRA LLC announces that the US Patent and Trademark Office (USPTO) has issued a patent (No. 12,551,706) protecting the use of dose adjusted budiodarone for the treatment of atrial fibrillation (AF), ...

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

New appointment strengthens executive leadership commensurate with launch of CARDAMYST™ (etripamil) nasal sprayMONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals ...

I bought this portable heart monitor for my aging parents — an expert says it's a 'great tool for early detection,' and it's on sale

With the paid subscription, you also get additional benefits such as cloud storage, blood pressure monitoring, medication tracking and, four times a year, customized reports and remote reviews by a ...
Morningstar

HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference

HeartBeam Recently Received US Food and Drug Administration (FDA) Clearance for First-Ever Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment Pivotal Milestone Unlocks Multiple Key ...
American College of Cardiology

Is Long COVID Associated With Autonomic Dysfunction?

Patients with long COVID may demonstrate persistent autonomic dysfunction that is similar to patients with pure autonomic failure when adjusted for age and sex, according to a study published Dec. 10 ...
MedPage Today

Etripamil Gets FDA Approval for At-Home Tachycardia Conversion

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced. The rapid-acting L-type calcium ...
Seeking Alpha

HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment

HeartBeam, Inc. (BEAT) (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...
Morningstar

HeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment

FDA Clearance Granted After Successful Appeal, Overturning Prior Not Substantially Equivalent (NSE) Outcome HeartBeam’s Credit-Card Sized Device Delivers Clinical-Grade Insights Directly to Patients ...
Hosted on MSN

HeartBeam (NASDAQ: BEAT) secures FDA 510(k) clearance for 12-lead ECG synthesis software following successful appeal

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, received FDA 510(k) clearance for its 12-lead ECG synthesis software for ...
BMJ

Cardiac arrhythmia assessment with patch electrocardiogram versus insertable cardiac monitor: a cohort study in endurance athletes with atrial fibrillation

Objectives The objective of this study was to assess the quality of ECG recordings and the concordance between the automatic detection of cardiac arrhythmia episodes by a patch ECG and an insertable ...